Weight loss field ex­pands as Pfiz­er's oral GLP-1 gath­ers com­par­isons to Novo's We­govy in PhII da­ta

Pfiz­er’s at­tempt to catch up in the weight loss mar­ket picked up steam on Mon­day with re­search show­ing the com­pa­ny’s GLP-1 ag­o­nist helped peo­ple with type 2 di­a­betes shed weight.

With da­ta pub­lished in the JA­MA net­work, led by Pfiz­er VP Adi­ti Sax­e­na, the Big Phar­ma took a step clos­er to stak­ing its spot in the bur­geon­ing R&D field for obe­si­ty drugs, many of which start­ed as di­a­betes meds, and are tout­ed as be­com­ing the biggest drug class in his­to­ry with more than $100 bil­lion on the line.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN